Catastrophic antiphospholipid syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:464343D68.6
Who is this for?
Show terms as
11Active trials27Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Catastrophic antiphospholipid syndrome (sometimes called CAPS or Asherson syndrome) is a rare and very serious form of antiphospholipid syndrome. In this condition, the immune system mistakenly makes antibodies called antiphospholipid antibodies that attack the body's own blood vessels. This causes widespread blood clots to form rapidly in multiple organs at the same time, usually over just a few days. The organs most commonly affected include the kidneys, lungs, brain, heart, and skin, but any organ can be involved. Because so many organs are damaged at once, CAPS is a life-threatening medical emergency. Symptoms depend on which organs are affected but can include kidney failure, difficulty breathing, confusion or stroke-like symptoms, skin changes, and abdominal pain. CAPS can occur in people who already have antiphospholipid syndrome or lupus, but it can also appear without warning in someone who has never been diagnosed with these conditions. Common triggers include infections, surgery, stopping blood-thinning medications, or other stressful events to the body. Treatment requires urgent hospitalization and typically involves a combination of blood thinners (anticoagulants like heparin), high-dose corticosteroids to reduce inflammation, and plasma exchange (a procedure that filters harmful antibodies from the blood). Intravenous immunoglobulin (IVIG) may also be used. In some cases, the biologic drug rituximab or eculizumab has been tried. Despite aggressive treatment, CAPS remains very dangerous, with a significant mortality rate, though outcomes have improved with modern combination therapy.

Also known as:

Key symptoms:

Sudden kidney failureDifficulty breathing or respiratory failureStroke or confusionSkin discoloration or livedo reticularis (net-like purple skin pattern)Heart problems including heart attackAbdominal pain from organ damageLow platelet count causing easy bruising or bleedingSeizuresVision changes or lossSwelling in the legsFatigue and general feeling of being very unwellGangrene of fingers or toesLiver problemsHigh blood pressure

Clinical phenotype terms (50)— hover any for plain English
Gastrointestinal infarctionsHP:0005244Acute encephalopathyHP:0006846MyocarditisHP:0012819Retinal arterial occlusionHP:0025326EclampsiaHP:0100601Abnormal jugular vein morphologyHP:3000042Antiphospholipid antibody positivityHP:0003613Microangiopathic hemolytic anemiaHP:0001937Deep venous thrombosisHP:0002625Peripheral thrombosisHP:0002641Arterial thrombosisHP:0004420Coombs-positive hemolytic anemiaHP:0004844
Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Mar 2026Impact of Disinfectant Caps on Nosocomial CLABSI

BDH-Klinik Hessisch Oldendorf

TrialNOT YET RECRUITING
Mar 2026A Post-marketing Observational Study of Oral Cholera Vaccine

Shanghai United Cell Biotechnology Co., Ltd — PHASE4

TrialNOT YET RECRUITING
Feb 2026A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain

Shandong Suncadia Medicine Co., Ltd. — PHASE1

TrialNOT YET RECRUITING
Jan 2026Drug-drug Interaction Study of Rifampin and Anaprazole Sodium

Xuanzhu Biopharmaceutical Co., Ltd. — PHASE4

TrialNOT YET RECRUITING
Jan 2026Exploration of Sintilimab + Bevacizumab + AG Chemotherapy as First-Line Treatment for Unresectable Advanced/Metastatic Cholangiocarcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University — PHASE2

TrialNOT YET RECRUITING
Dec 2025Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. — PHASE3

TrialRECRUITING
Dec 2025Adductor Canal Block With IPACK Versus Genicular Nerves Block With IPACK for Post-operative Analgesia

Minia University — NA

TrialNOT YET RECRUITING
Nov 2025A Study to Learn How Different Forms of the Study Medicine Called Prazosin Are Taken up Into the Blood in Healthy Adults

Pfizer — PHASE1

TrialRECRUITING
Oct 2025Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children

Sun Yat-sen University — PHASE2

TrialNOT YET RECRUITING
Sep 2025A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

Chipscreen Biosciences, Ltd. — PHASE1, PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Catastrophic antiphospholipid syndrome.

11 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

11 recruitingView all trials with filters →
Phase 34 trials
A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients
Phase 3
Active
PI: Yuankai Shi (Cancer Institute and Hospital, Chinese Academy of ) · Sites: Beijing, Beijing Municipality; Zhengzhou, Henan +1 more · Age: 1899 yrs
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
Phase 3
Actively Recruiting
· Sites: Hefei, Anhui; Hefei, Anhui +68 more · Age: 1875 yrs
TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail
Phase 3
Active
· Sites: Beijing, Beijing Municipality; Beijing, Beijing Municipality · Age: 1875 yrs
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
Phase 3
Actively Recruiting
· Sites: Beijing, Beijing Municipality; Beijing, Beijing Municipality +25 more · Age: 1850 yrs
Phase 22 trials
Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin
Phase 2
Actively Recruiting
· Sites: Hangzhou, Zhejiang · Age: 1875 yrs
Zhibitai Capsules for the Treatment of Primary Hyperlipidemia
Phase 2
Actively Recruiting
· Sites: Changsha, Hunan · Age: 1875 yrs
Phase 14 trials
A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants
Phase 1
Actively Recruiting
PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (Eli Lilly and Company) · Sites: San Antonio, Texas; Salt Lake City, Utah · Age: 1855 yrs
Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
Phase 1
Actively Recruiting
PI: Study Director (Nurix Therapeutics) · Sites: Lincoln, Nebraska · Age: 1955 yrs
Evaluating the Effect Of Rifaximin on the Gut Microbiota and Metabolome in SIBO Using CapScan®
Phase 1
Actively Recruiting
PI: George Triadafilopoulos (Silicon Valley Gastroenterology) · Sites: Mountain View, California · Age: 1880 yrs
A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors
Phase 1
Actively Recruiting
· Sites: Beijing, Beijing Municipality; Shanghai, Shanghai Municipality +2 more · Age: 1899 yrs

Specialists

Showing 25 of 27View all specialists →
SC
Shruti Chaturvedi
BALTIMORE, MD
Specialist
2 Catastrophic antiphospholipid syndrome publications
IR
Ignasi Rodriguez-Pintó
Specialist
2 Catastrophic antiphospholipid syndrome publications
NR
Nikhil Ranjan
Specialist
2 Catastrophic antiphospholipid syndrome publications
EB
Evan M Braunstein
BALTIMORE, MD
Specialist
2 Catastrophic antiphospholipid syndrome publications
DF
Daniel Flores-Guerrero
Specialist
2 Catastrophic antiphospholipid syndrome publications
KH
Kathy Haddaway
Specialist
2 Catastrophic antiphospholipid syndrome publications
AR
Alexis Reed
Specialist
2 Catastrophic antiphospholipid syndrome publications
MS
Michael B Streiff
BALTIMORE, MD
Specialist
2 Catastrophic antiphospholipid syndrome publications
RB
Robert A Brodsky
Specialist
2 Catastrophic antiphospholipid syndrome publications
BL
Brenda López-Benjume
Specialist
2 Catastrophic antiphospholipid syndrome publications
GG
Gloria F Gerber
BALTIMORE, MD
Specialist
2 Catastrophic antiphospholipid syndrome publications
KM
Keith R McCrae
CLEVELAND, OH
Specialist
2 Catastrophic antiphospholipid syndrome publications
MP
Michelle Petri
BALTIMORE, MD
Specialist
2 Catastrophic antiphospholipid syndrome publications
MC
Mark A Crowther
Specialist
2 Catastrophic antiphospholipid syndrome publications
GE
Gerard Espinosa
LOS ANGELES, CA
Specialist
3 Catastrophic antiphospholipid syndrome publications
YS
Yuankai Shi
Specialist
PI on 5 active trials256 Catastrophic antiphospholipid syndrome publications
UC
Use Central Contact
Specialist
PI on 28 active trials
BP
Benjamin Philosophe, MD, PHD
BALTIMORE, MD
Specialist
PI on 1 active trial
MM
Mohamed Al-Ibrahim, MD
BALTIMORE, MD
Specialist
PI on 3 active trials
MA
Mohamed Al-Ibrahim
BALTIMORE, MD
Specialist
PI on 2 active trials
RE
Robert Enns
Specialist
PI on 1 active trial
SB
Steven D Brooks
Specialist
PI on 1 active trial
AS
Alpesh Shah
PEARLAND, TX
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Catastrophic antiphospholipid syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Catastrophic antiphospholipid syndromeForum →

No community posts yet. Be the first to share your experience with Catastrophic antiphospholipid syndrome.

Start the conversation →

Latest news about Catastrophic antiphospholipid syndrome

Disease timeline:

New recruiting trial: Efficacy and Safety of HSK16149 Capsule in Chinese Patients With Diabetic Peripheral Neuropathic Pain Who Had an Inadequate Response to Pregabalin

A new clinical trial is recruiting patients for Catastrophic antiphospholipid syndrome

New recruiting trial: Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets

A new clinical trial is recruiting patients for Catastrophic antiphospholipid syndrome

New recruiting trial: A Phase Ia/Ib Clinical Study of GH56 Capsules in Subjects With MTAP-Deleted Advanced Solid Tumors

A new clinical trial is recruiting patients for Catastrophic antiphospholipid syndrome

New recruiting trial: A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

A new clinical trial is recruiting patients for Catastrophic antiphospholipid syndrome

New recruiting trial: Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

A new clinical trial is recruiting patients for Catastrophic antiphospholipid syndrome

New recruiting trial: Using a mHealth App to Improve Quality-of-Life Outcomes in Black Prostate Cancer Survivors

A new clinical trial is recruiting patients for Catastrophic antiphospholipid syndrome

New recruiting trial: Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands

A new clinical trial is recruiting patients for Catastrophic antiphospholipid syndrome

New recruiting trial: Radiation Cystitis Treated With Pentosan Polysulfate Sodium Trial

A new clinical trial is recruiting patients for Catastrophic antiphospholipid syndrome

New recruiting trial: A Study to Evaluate the Efficacy and Safety of CS32582 in Participants With Moderate to Severe Plaque Psoriasis

A new clinical trial is recruiting patients for Catastrophic antiphospholipid syndrome

New recruiting trial: Zhibitai Capsules for the Treatment of Primary Hyperlipidemia

A new clinical trial is recruiting patients for Catastrophic antiphospholipid syndrome

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.What organs have been affected, and what is the expected recovery for each?,How long will I need to take blood-thinning medication, and what are the risks?,What are the warning signs that CAPS could be coming back?,Are there activities or medications I should avoid while on blood thinners?,Should I be tested for lupus or other autoimmune conditions?,What should I do if I need surgery or a dental procedure in the future?,Are my family members at risk for antiphospholipid syndrome?

Common questions about Catastrophic antiphospholipid syndrome

What is Catastrophic antiphospholipid syndrome?

Catastrophic antiphospholipid syndrome (sometimes called CAPS or Asherson syndrome) is a rare and very serious form of antiphospholipid syndrome. In this condition, the immune system mistakenly makes antibodies called antiphospholipid antibodies that attack the body's own blood vessels. This causes widespread blood clots to form rapidly in multiple organs at the same time, usually over just a few days. The organs most commonly affected include the kidneys, lungs, brain, heart, and skin, but any organ can be involved. Because so many organs are damaged at once, CAPS is a life-threatening medica

How is Catastrophic antiphospholipid syndrome inherited?

Catastrophic antiphospholipid syndrome follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Catastrophic antiphospholipid syndrome typically begin?

Typical onset of Catastrophic antiphospholipid syndrome is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Catastrophic antiphospholipid syndrome?

Yes — 11 recruiting clinical trials are currently listed for Catastrophic antiphospholipid syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Catastrophic antiphospholipid syndrome?

25 specialists and care centers treating Catastrophic antiphospholipid syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.